CULS Conversion and Additional Listing

RNS Number : 0192W

Alliance Pharma PLC

19 December 2013

 



For immediate release

19 December 2013

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

CULS Conversion and Additional Listing

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that pursuant to the Compulsory Conversion notice dated 7^th November 2013 it will automatically convert the outstanding £3,525 nominal value of the Company's 8% Convertible Unsecured Loan Stock into Ordinary Share Capital. Accordingly, the Company has allotted 16,785 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to admission of the Ordinary Shares to trading on AIM.

Application has been made by Alliance for the 16,785 Ordinary Shares to be admitted to trading on AIM, and it is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 31 December 2013.

Following conversion and allotment, Alliance will have 264,080,873 Ordinary Shares and no remaining 8% Convertible Unsecured Loan Stock in issue.

.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

MSCFMMMZDLRGFZM